Patents Examined by Kara R McMillian
  • Benzimidazole anthelmintic compositions
    Patent number: 9283176
    Abstract: The present invention provides a veterinary anthelmintic composition that includes: at least 10% w/v of a benzimidazole anthlemintic; and b) a water-immiscible solvent system, which comprises a lactone solvent, an essential oil, and surfactant.
    Type: Grant
    Filed: October 5, 2009
    Date of Patent: March 15, 2016
    Assignee: Zoetis Services LLC
    Inventors: Robert Bruce Albright, Moses Collumbus Lawrence, Shobhan Shashikant Sabnis, Sivaja Ranjan
  • Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive
    Patent number: 9238073
    Abstract: A pharmaceutical composition is provided which contains a water soluble acid salt of a sympathomimetic amine, e.g., pseudoephedrine, and an additive, e.g., a volatile amine or other odorant, that is co-distillable, e.g., by steam distillation, with the sympathomimetic amine and/or its derivatives, e.g., its free base.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: January 19, 2016
    Assignee: Wyeth LLC
    Inventors: David Hugh Giamalva, Gary Bruce Anderson
  • Vector delivery-based microbicides
    Patent number: 9233101
    Abstract: A new class of anti-microbial agents and methods for preventing or reducing the risk of sexually transmitted infections and/or diseases is provided. Preferably, these anti-microbial agents are also contraceptive and, thus, also prevent or reduce the risk of unplanned pregnancies. The anti-microbial agents comprise a delivery vector having anti-microbial activity (and preferably contraceptive activity) coupled with a nitric oxide donor moiety.
    Type: Grant
    Filed: August 14, 2006
    Date of Patent: January 12, 2016
    Assignee: Rush University Medical Center
    Inventors: Robert Anthony Anderson, Jr., Calvin J. Chany, II
  • Compositions, methods of use, and methods of treatment
    Patent number: 9233109
    Abstract: Briefly described, embodiments of this disclosure, among others, include compositions, pharmaceutical compositions, methods of treating nicotine dependence, methods of treating a subject who smokes and has a risk for depression or other neuropsychiatric disorder, method of treating a subject who smokes and has a risk for depression or other neuropsychiatric disorders, and the like.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: January 12, 2016
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Roger Lee Papke, Adriaan Willem Bruijnzeel, Sara Jo Nixon, William Kem, Ferenc Soti
  • Cleansing composition
    Patent number: 9212339
    Abstract: The present invention relates to a cleansing composition comprising an anti-microbial agent and a sulphur binding and/or oxidizing agent, and wherein the pH of the composition is 7 or lower, to a method for preparing the cleansing composition and its use.
    Type: Grant
    Filed: December 29, 2006
    Date of Patent: December 15, 2015
    Assignee: Laugeman Laboratories B.V.
    Inventor: Frits Jan Rudolf Laugeman
  • 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of inflammatory or immunological disorders
    Patent number: 9206186
    Abstract: Provided herein are 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity. These compounds are useful for the treatment of diseases associated with CCR3 activity, including but not limited to, atopic dermatitis, allergic rhinitis, rheumatoid arthritis, Grave's disease, HIV infection, Alzheimer's disease, atherosclerosis and other inflammatory and/or immunological disorders.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: December 8, 2015
    Assignee: AXIKIN PHARMACEUTICALS, INC.
    Inventors: Yingfu Li, Kevin Bacon, Hiromi Sugimoto, Keiko Fukushima, Kentaro Hashimoto, Makiko Marumo, Toshiya Moriwaki, Noriko Nunami, Naoki Tsuno, Klaus Urbahns, Nagahiro Yoshida
  • Materials and methods for inhibiting mamalian S-nitrosoglutathione reductase
    Patent number: 9198909
    Abstract: The current study reports novel inhibitors of s-nitrosoglutathione reductase (GSNOR) identified that specifically inhibit GSNOR among the alcohol dehydrogenases. These inhibitors may bind into the GSNO binding site and inhibit GSNOR at multiple places in its kinetic pathway. These molecules inhibit GSNOR in a dose dependent manner and demonstrate that GSNOR actively regulates the s-nitrosylation of proteins against incoming low molecular weight nitrosothiols. These compounds are useful in method of treatment of diseases such as asthma, chronic obstructive pulmonary disease, heart disease, heart failure, heart attack, hypertension, atherosclerosis, restenosis, impotence, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, stroke, septic shock, cardiogenic shock, endotoxic shock, toxic shock syndrome, systemic inflammatory response syndrome, and other inflammatory diseases.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: December 1, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventor: Paresh Sanghani
  • Arylamide compounds and compositions and uses thereof
    Patent number: 9192623
    Abstract: The present invention discloses ophthalmic and otic compositions of facially amphiphilic antimicrobial polymers and oligomers and their uses, including their use in methods for treating and preventing ophthalmic infections and otic infections in humans and animals.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: November 24, 2015
    Assignee: Cellceutix Corporation
    Inventor: Richard W. Scott
  • Substituted phenyl(oxy/thio)alkanol derivatives
    Patent number: 9187431
    Abstract: The present invention relates to novel substituted phenyl(oxy/thio)alkanol derivatives, to processes for preparing these compounds, to compositions comprising these compounds and to their use as biologically active compounds, in particular for controlling harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: November 17, 2015
    Assignee: Bayer Intellectual Property GMBH
    Inventors: Carl Friedrich Nising, Klaus Kunz, Jörg Nico Greul, Hendrik Helmke, Gorka Peris, Jürgen Benting, Peter Dahmen, Isolde Häuser-Hahn, Ines Heinemann, Christian Paulitz, Dirk Schmutzler, Ulrike Wachendorff-Neumann, Christoph Andreas Braun, Ruth Meissner, Hiroyuki Hadano
  • Neurodegenerative diseases and methods of modeling
    Patent number: 9180114
    Abstract: This invention relates to methods for neuroprotection, promoting survival of motor neurons and the treatment of motor neuron diseases by preventing cell signaling through the classic prostaglandin D2 receptor DP1.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: November 10, 2015
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Kevin Eggan, Francesco Paolo DiGiorgio
  • Stable bortezomib formulations
    Patent number: 9180093
    Abstract: Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: November 10, 2015
    Assignee: Innopharma, Inc.
    Inventors: Kumaresh Soppimath, Satish Pejaver, Kanaiyalal R. Patel, Lakkaraju Dasaradhi, Rama Sodum, Hari Desu, Navneet Puri
  • Parasiticidal compositions comprising multiple active agents, methods and uses thereof
    Patent number: 9173403
    Abstract: This invention relates to compositions for combating ectoparasites and endoparasites in animals, comprising at least one 1-arylpyrazole, at least one macrocyclic lactone, at least one insect growth regulator, and at least one anthelmintic compound in combination with a pharmaceutically acceptable carrier. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: November 3, 2015
    Assignee: MERIAL, INC.
    Inventors: Joseph K. Rosentel, Jr., Monica Tejwani, Arima Das-Nandy
  • 8-hydroxy quinoline derivatives
    Patent number: 9169211
    Abstract: The present invention describes a method for the treatment of a neurological condition in a subject which comprises administering to a subject in need thereof a therapeutically effect amount of a compound of the formula or pharmaceutically acceptable salts, hydrates, or solvates thereof.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: October 27, 2015
    Assignee: PRANA BIOTECHNOLOGY LIMITED
    Inventors: Kevin Jeffrey Barnham, Elisabeth Colette Louise Gautier, Gaik Beng Kok, Guy Krippner
  • Levothyroxine formulations
    Patent number: 9168239
    Abstract: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a lyophilized solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 2 to 4 milligrams mannitol.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: October 27, 2015
    Assignee: Fresenius Kabi USA, LLC
    Inventors: John Zhiqiang Jiang, Arunya Usayapant, George Monen
  • Levothyroxine formulations
    Patent number: 9168238
    Abstract: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a lyophilized solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 2 to 4 milligrams mannitol.
    Type: Grant
    Filed: March 8, 2015
    Date of Patent: October 27, 2015
    Assignee: Fresenius Kabi USA, LLC
    Inventors: John Zhiqiang Jiang, Arunya Usayapant, George Monen
  • Pharmaceutical composition and method for treating hypogonadism
    Patent number: 9132089
    Abstract: A pharmaceutical composition useful for treating hypogonadism is disclosed. The composition comprises an androgenic or anabolic steroid, a C1-C4 alcohol, a penetration enhancer such as isopropyl myristate, and water. Also disclosed is a method for treating hypogonadism utilizing the composition.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: September 15, 2015
    Assignees: BESINS HEALTHCARE INC., UNIMED PHARMACEUTICALS, LLC
    Inventors: Robert E. Dudley, Dominique Drouin
  • Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
    Patent number: 9125859
    Abstract: This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: September 8, 2015
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Ben Whalley, Claire Williams, Gary Stephens, Takashi Futamura
  • Pharmaceutical composition and method for treating hypogonadism
    Patent number: 9125816
    Abstract: A pharmaceutical composition useful for treating hypogonadism is disclosed. The composition comprises an androgenic or anabolic steroid, a C1-C4 alcohol, a penetration enhancer such as isopropyl myristate, and water. Also disclosed is a method for treating hypogonadism utilizing the composition.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: September 8, 2015
    Assignees: BESINS HEALTHCARE INC., UNIMED PHARMACEUTICALS, LLC
    Inventors: Robert E. Dudley, Dominique Drouin
  • Morphinan derivatives for the treatment of drug overdose
    Patent number: 9119848
    Abstract: The instant application relates to morphinan derivatives of Formula I with sustained effectiveness in treating drug toxicity and overdose:
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: September 1, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Bernard Silverman, Fen-Ni Fu, Chengyun Guo
  • Stable bortezomib formulations
    Patent number: 9107821
    Abstract: Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: August 18, 2015
    Assignee: Innopharma, Inc.
    Inventors: Kumaresh Soppimath, Satish Pejaver, Kanaiyalal R. Patel, Lakkaraju Dasaradhi, Rama Sodum, Hari Desu, Navneet Puri